Effectiveness and Safety of Weekly Therapy Versus 3-weekly Therapy of Paclitaxel Plus Carboplatin in Women with Ovarian Cancer: a Protocol of Systematic Review and Meta-analysis

Overview

Journal BMJ Open

Specialty General Medicine

Date 2022 Mar 17

PMID 35296476

Authors

Weitao Qiu

Yu Fu

Yun Dang

Bingxin Cai

Shumei Tuo

Baohong Mao

Ru Lin

Qing Liu

Yilin Li

Affiliations

Soon will be listed here.

Abstract

Introduction: Network meta-analyses have confirmed that paclitaxel plus carboplatin could improve progression-free survival (PFS) and overall survival (OS) compared with platinum alone. However, detailed implementation schedule (weekly or 3-weekly therapy) was not specified in clinical practice guidelines. Evidence from studies is also inconsistent. We will conduct a systematic review and meta-analysis to evaluate the benefits and harms of weekly therapy and 3-weekly therapy of paclitaxel combined with carboplatin in women with ovarian cancer.

Methods: We will search PubMed, EMBASE and the Cochrane Library databases to include relevant randomised controlled trials comparing weekly therapy versus 3-weekly therapy of paclitaxel combined with carboplatin for women with ovarian cancer. Random-effects model will be used to pool data for patient-reported outcomes including survival rate, OS, PFS and adverse events. Grading of Recommendation, Assessment, Development and Evaluation approach will be used to rate the quality of evidence.

Ethics And Dissemination: This systematic review and meta-analysis will be based on published data and does not therefore require specific ethical approval or consent for participation. The results will be published in a peer-reviewed journal.

Osf Registration Number: 10.17605/OSF.IO/GJUMA.

References

Baird R, Tan D, Kaye S . Weekly paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev Clin Oncol. 2010; 7(10):575-82. DOI: 10.1038/nrclinonc.2010.120. View

Qu C, Sun G, Yang S, Tian J, Si J, Wang Y . Toxicities of different first-line chemotherapy regimens in the treatment of advanced ovarian cancer: A network meta-analysis. Medicine (Baltimore). 2017; 96(2):e5797. PMC: 5266167. DOI: 10.1097/MD.0000000000005797. View

Jiang X, Rui X, Guo C, Huang Y, Li Q, Xu Y . A network meta-analysis of eight chemotherapy regimens for treatment of advanced ovarian cancer. Oncotarget. 2016; 8(12):19125-19136. PMC: 5386673. DOI: 10.18632/oncotarget.13253. View

Shamseer L, Moher D, Clarke M, Ghersi D, Liberati A, Petticrew M . Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015; 350:g7647. DOI: 10.1136/bmj.g7647. View

Ge L, Tian J, Li Y, Pan J, Li G, Wei D . Association between prospective registration and overall reporting and methodological quality of systematic reviews: a meta-epidemiological study. J Clin Epidemiol. 2017; 93:45-55. DOI: 10.1016/j.jclinepi.2017.10.012. View

Fleming N, Coleman R, Tung C, Westin S, Hu W, Sun Y . Phase II trial of bevacizumab with dose-dense paclitaxel as first-line treatment in patients with advanced ovarian cancer. Gynecol Oncol. 2017; 147(1):41-46. PMC: 5605462. DOI: 10.1016/j.ygyno.2017.07.137. View

Katsumata N, Yasuda M, Takahashi F, Isonishi S, Jobo T, Aoki D . Dose-dense paclitaxel once a week in combination with carboplatin every 3 weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet. 2009; 374(9698):1331-8. DOI: 10.1016/S0140-6736(09)61157-0. View

Thigpen T, duBois A, McAlpine J, Disaia P, Fujiwara K, Hoskins W . First-line therapy in ovarian cancer trials. Int J Gynecol Cancer. 2011; 21(4):756-62. DOI: 10.1097/IGC.0b013e31821ce75d. View

Havrilesky L, Alvarez A, Sayer R, Lancaster J, Soper J, Berchuck A . Weekly low-dose carboplatin and paclitaxel in the treatment of recurrent ovarian and peritoneal cancer. Gynecol Oncol. 2002; 88(1):51-7. DOI: 10.1006/gyno.2002.6859. View

10.

Ngoi N, Syn N, Goh R, Goh B, Huang R, Soon Y . Weekly versus tri-weekly paclitaxel with carboplatin for first-line treatment in women with epithelial ovarian cancer. Cochrane Database Syst Rev. 2022; 2:CD012007. PMC: 8859866. DOI: 10.1002/14651858.CD012007.pub2. View

11.

Marchetti C, De Felice F, Musella A, Palaia I, Monti M, Musio D . Weekly versus three weeks chemotherapy for advanced ovarian cancer: a meta-analysis. Oncotarget. 2016; 7(36):58709-58715. PMC: 5295464. DOI: 10.18632/oncotarget.11094. View

12.

Pignata S, Scambia G, Katsaros D, Gallo C, Pujade-Lauraine E, De Placido S . Carboplatin plus paclitaxel once a week versus every 3 weeks in patients with advanced ovarian cancer (MITO-7): a randomised, multicentre, open-label, phase 3 trial. Lancet Oncol. 2014; 15(4):396-405. DOI: 10.1016/S1470-2045(14)70049-X. View

13.

Blagden S, Cook A, Poole C, Howells L, McNeish I, Dean A . Weekly platinum-based chemotherapy versus 3-weekly platinum-based chemotherapy for newly diagnosed ovarian cancer (ICON8): quality-of-life results of a phase 3, randomised, controlled trial. Lancet Oncol. 2020; 21(7):969-977. PMC: 7327508. DOI: 10.1016/S1470-2045(20)30218-7. View

14.

Gonzalez-Martin A, Gladieff L, Tholander B, Stroyakovsky D, Gore M, Scambia G . Efficacy and safety results from OCTAVIA, a single-arm phase II study evaluating front-line bevacizumab, carboplatin and weekly paclitaxel for ovarian cancer. Eur J Cancer. 2013; 49(18):3831-8. DOI: 10.1016/j.ejca.2013.08.002. View

15.

Guyatt G, Oxman A, Kunz R, Vist G, Falck-Ytter Y, Schunemann H . What is "quality of evidence" and why is it important to clinicians?. BMJ. 2008; 336(7651):995-8. PMC: 2364804. DOI: 10.1136/bmj.39490.551019.BE. View

16.

Chan J, Brady M, Penson R, Huang H, Birrer M, Walker J . Weekly vs. Every-3-Week Paclitaxel and Carboplatin for Ovarian Cancer. N Engl J Med. 2016; 374(8):738-48. PMC: 5081077. DOI: 10.1056/NEJMoa1505067. View

17.

Page M, McKenzie J, Bossuyt P, Boutron I, Hoffmann T, Mulrow C . The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. BMJ. 2021; 372:n71. PMC: 8005924. DOI: 10.1136/bmj.n71. View

18.

Sharma R, Graham J, Mitchell H, Brooks A, Blagden S, Gabra H . Extended weekly dose-dense paclitaxel/carboplatin is feasible and active in heavily pre-treated platinum-resistant recurrent ovarian cancer. Br J Cancer. 2009; 100(5):707-12. PMC: 2653750. DOI: 10.1038/sj.bjc.6604914. View

19.

Morgan R, McNeish I, Cook A, James E, Lord R, Dark G . Objective responses to first-line neoadjuvant carboplatin-paclitaxel regimens for ovarian, fallopian tube, or primary peritoneal carcinoma (ICON8): post-hoc exploratory analysis of a randomised, phase 3 trial. Lancet Oncol. 2020; 22(2):277-288. PMC: 7616995. DOI: 10.1016/S1470-2045(20)30591-X. View

20.

Cumpston M, Li T, Page M, Chandler J, Welch V, Higgins J . Updated guidance for trusted systematic reviews: a new edition of the Cochrane Handbook for Systematic Reviews of Interventions. Cochrane Database Syst Rev. 2019; 10:ED000142. PMC: 10284251. DOI: 10.1002/14651858.ED000142. View